Quote | Cybin Inc. (NYSE:CYBN)
Last: | $0.35 |
---|---|
Change Percent: | -0.74% |
Open: | $0.3526 |
Close: | $0.35 |
High: | $0.3589 |
Low: | $0.3451 |
Volume: | 2,727,669 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Cybin Inc. (NYSE:CYBN)
2024-04-29 13:37:07 ET More on psychedelic drug developers Psychedelic drugs market to break $7B in 2029 led by these 3 meds Cybin spikes after FDA breakthrough tag for psychedelic therapy Psychedelic stocks gain after FDA priority review for MDMA therapy ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at th...
Message Board Posts | Cybin Inc. (NYSE:CYBN)
Subject | By | Source | When |
---|---|---|---|
$CYBN The trading up | Nosnibor | investorshub | 04/27/2023 11:57:26 PM |
bears are running | Reyeton | investorshub | 04/27/2023 7:22:01 PM |
$CYBN The now last up | Reyeton | investorshub | 04/27/2023 2:17:05 PM |
MomentumIts trading | sagedono | investorshub | 04/27/2023 2:53:31 AM |
$CYBN what does this mean? | sagedono | investorshub | 04/26/2023 3:14:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Cybin Inc. Company Name:
CYBN Stock Symbol:
NYSE Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at th...
- Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 - Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekl...